Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
April 10, 2008
Millennium purchase may open up avenues for more sales??
Analysis of: Takeda to Buy Millennium In $8.8 Billion Deal | online.wsj.com
Author: GLG Expert Contributor
Japan's biggest (by revenue) drug manufacturer has placed a bid For Millennium and it's primary product Velcade.
April 10, 2008
Sickle Cell Anemia: Does Icagen, Inc have an answer in senicapoc (ICA-17043)?
Analysis of: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
"Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration." This appears to decrease hemolysis and increase hemoglobin levels.
April 9, 2008
Bexarotene (Ligand) It's SPIRIT is alive in a subset of lung cancer patients.
Analysis of: Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II | jco.ascopubs.org
Author: GLG Expert Contributor
This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!
April 9, 2008
Oncophage(R) : Let's wait until the results are duplicated in Costa Rica.......
Analysis of: Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???
April 4, 2008
Genetic drivers of lung cancer risk identified.
Analysis of: Studies Find Genetic Link to Smoking | www.nytimes.com
Author: GLG Expert Contributor
Gene driven nicotine receptors will predispose to increased smoking. What will this lead to?? Increased addiction due to mutations increases cancer risk.
April 2, 2008
An unmet need still unmet, tough luck for Pfizer
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment | online.wsj.com
Author: GLG Expert Contributor
Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)
April 1, 2008
Amgen, Well at least they have Aranesp. (Whoops!)
Analysis of: Unexpected Toxicity with Panitumumab Plus Chemotherapy-Bevacizumab Combo in Colorectal Cancer | www.oncology-times.com
Author: GLG Expert Contributor
Vectibix's undue toxicity without obvious benefits punctures Amgen's hope of finding a first or even second line use for this EGFR directed monoclonal antibody.
April 1, 2008
Implications of mechanism's of action? Who cares if it works!
Analysis of: OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy | www.pipelinereview.com
Author: GLG Expert Contributor
OXiGENE, Inc's., ZYBRESTAT(TM) (fosbretabulin), a vascular disrupting agent (?) is being given with Taxol/Carboplatin (T/C) in a randomized Phase II study. Soooo T/C with or without ZYBRESTAT.
March 31, 2008
Well at least they have Procrit (Whoops!)
Analysis of: Cancer risk seen with J&J foot gel: FDA | uk.reuters.com
Author: GLG Expert Contributor
 "A Johnson & Johnson foot gel used by diabetics may increase the risk of cancer and death, U.S. health officials said on Thursday in announcing an investigation into the issue."
March 31, 2008
New Therapy for Hormone Refractory Prostate CA. Maybe!!!
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Phase II results ++

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 466

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T01:45:15.453